Drug Profile

KT 501

Alternative Names: KT-501

Latest Information Update: 25 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kali Therapeutics
Class Recombinant fusion proteins; T lymphocyte cell therapies
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Autoimmune disorders

Most Recent Events

11 Jun 2025 Kali therapeutics plans a phase I first-in-human trial for Rheumatoid arthritis in USA (SC, Injection) in December 2025 (NCT07234773)
11 Jun 2025 Preclinical trials in Autoimmune disorders in USA (Parenteral)
11 Jun 2025 Pharmacodynamics data from a preclinical trial in Autoimmune disorders presented at the 26th Annual Congress of the European League Against Rheumatism (EULAR-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com